Literature DB >> 15096455

Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death.

Aaron E Cozen1, Hideaki Moriwaki, Michal Kremen, Mary Beth DeYoung, Helén L Dichek, Katherine I Slezicki, Stephen G Young, Murielle Véniant, David A Dichek.   

Abstract

BACKGROUND: Human atherosclerotic lesions contain elevated levels of urokinase plasminogen activator (uPA), expressed predominantly by macrophages. METHODS AND
RESULTS: To test the hypothesis that macrophage-expressed uPA contributes to the progression and complications of atherosclerosis, we generated transgenic mice with macrophage-targeted overexpression of uPA. The uPA transgene was bred into the apolipoprotein E-null background, and transgenic mice and nontransgenic littermate controls were fed an atherogenic diet. uPA-transgenic mice had significantly elevated uPA activity in the atherosclerotic artery wall, of a magnitude similar to elevations reported in atherosclerotic human arteries. Compared with littermate controls, uPA-transgenic mice had accelerated atherosclerosis, dilated aortic roots, occlusive proximal coronary artery disease, myocardial infarcts, and early mortality.
CONCLUSIONS: These data support the hypothesis that overexpression of uPA by artery wall macrophages is atherogenic and suggest that uPA inhibitors might be therapeutically useful.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096455     DOI: 10.1161/01.CIR.0000127369.24127.03

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

1.  Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice.

Authors:  Jie Hong Hu; Liang Du; Talyn Chu; Goro Otsuka; Nagadhara Dronadula; Mia Jaffe; Sean E Gill; William C Parks; David A Dichek
Journal:  Circulation       Date:  2010-03-29       Impact factor: 29.690

2.  The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling.

Authors:  Elina Minami; Chiara Castellani; Laura Malchodi; Jennifer Deem; Kate Bertko; Jessica Meznarich; Monja Dishmon; Charles E Murry; April Stempien-Otero
Journal:  J Mol Cell Cardiol       Date:  2010-04-07       Impact factor: 5.000

3.  Macrophage-specific expression of urokinase-type plasminogen activator promotes skeletal muscle regeneration.

Authors:  Margaret L Novak; Scott C Bryer; Ming Cheng; Mai-Huong Nguyen; Kevin L Conley; Andrew K Cunningham; Bing Xue; Thomas H Sisson; Jae-Sung You; Troy A Hornberger; Timothy J Koh
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

4.  Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms.

Authors:  Haruhito A Uchida; Aruna Poduri; Venkateswaran Subramanian; Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-25       Impact factor: 8.311

5.  ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2016-03-25       Impact factor: 5.922

6.  Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.

Authors:  Michal Kremen; Ranjini Krishnan; Isaac Emery; Jie Hong Hu; Katherine I Slezicki; Alyssa Wu; Kun Qian; Liang Du; Abigail Plawman; April Stempien-Otero; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

7.  Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein.

Authors:  Abigail S Haka; Inna Grosheva; Rajesh K Singh; Frederick R Maxfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

8.  A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies.

Authors:  Paraskevi Briassouli; Marc K Halushka; Joanne H Reed; Yair Molad; Karen Fox-Talbot; Lucas Buyon; Edwin Guzman; Achiau Ludomirsky; Robert M Clancy; Jill P Buyon
Journal:  Rheumatology (Oxford)       Date:  2013-04-18       Impact factor: 7.580

9.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

10.  Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.

Authors:  Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith
Journal:  J Vasc Surg       Date:  2009-08-22       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.